We could not find any results for:
Make sure your spelling is correct or try broadening your search.
BURLINGTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment...
Company will accelerate Revita® weight maintenance clinical study REMAIN-1; open label data from REVEAL-1 cohort expected in Q4 2024 and mid-point data analysis for REMAIN-1 anticipated in Q2 2025...
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment...
Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p<0.01) and liver triglycerides by 67% (p<0.0001) compared to placebo two months...
Initiation of Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 based drugs expected in the second half of 2024 Topline data from Revitalize-1...
First 14 participants with at least six months of follow up continue to demonstrate sustained improvements in blood glucose and weight with reduction in T2D medication utilization after a single...
BURLINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.93 | -17.4812030075 | 5.32 | 5.3432 | 3.98 | 261001 | 4.51225196 | CS |
4 | -2.41 | -35.4411764706 | 6.8 | 7.05 | 3.98 | 190679 | 5.35658983 | CS |
12 | -3.06 | -41.0738255034 | 7.45 | 7.89 | 3.98 | 159707 | 6.19817483 | CS |
26 | -9.36 | -68.0727272727 | 13.75 | 14.5 | 3.98 | 287005 | 7.80077132 | CS |
52 | -9.36 | -68.0727272727 | 13.75 | 14.5 | 3.98 | 287005 | 7.80077132 | CS |
156 | -9.36 | -68.0727272727 | 13.75 | 14.5 | 3.98 | 287005 | 7.80077132 | CS |
260 | -9.36 | -68.0727272727 | 13.75 | 14.5 | 3.98 | 287005 | 7.80077132 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions